Immix Biopharma (IMMX) to Release Earnings on Monday

Immix Biopharma (NASDAQ:IMMX) is projected to announce its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Immix Biopharma to post earnings of ($0.16) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

Immix Biopharma Stock Performance

Shares of NASDAQ:IMMX opened at $10.00 on Monday. The firm has a market capitalization of $529.60 million, a PE ratio of -12.99 and a beta of 0.25. Immix Biopharma has a 52-week low of $1.34 and a 52-week high of $10.71. The firm has a fifty day moving average of $6.87 and a 200 day moving average of $4.78.

Institutional Trading of Immix Biopharma

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new position in Immix Biopharma in the 4th quarter worth $386,000. KVP Capital Advisors LP bought a new stake in shares of Immix Biopharma during the 4th quarter valued at about $1,205,000. XTX Topco Ltd increased its position in shares of Immix Biopharma by 32.0% during the fourth quarter. XTX Topco Ltd now owns 46,394 shares of the company’s stock valued at $243,000 after buying an additional 11,241 shares during the period. Quadrature Capital Ltd purchased a new position in shares of Immix Biopharma during the fourth quarter valued at about $116,000. Finally, Perceptive Advisors LLC bought a new position in Immix Biopharma in the fourth quarter worth about $1,773,000. Institutional investors own 11.26% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Citizens Jmp started coverage on Immix Biopharma in a research note on Monday, March 9th. They set an “outperform” rating and a $23.00 price target for the company. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday. Mizuho initiated coverage on Immix Biopharma in a report on Monday, February 9th. They set an “outperform” rating and a $14.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Immix Biopharma presently has an average rating of “Hold” and an average price target of $15.00.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.